sintilimab

Overview

Sintilimab is an anti-PD-1 monoclonal antibody targeting PDCD1. It is evaluated for locally advanced and recurrent/metastatic nasopharyngeal carcinoma (NPC).

Evidence in the corpus

• Phase III sintilimab + concurrent chemoradiation (CCRT) in locally advanced NPC (NCT03700476, n=425): event-free survival HR 0.59; 36-month EFS 86% vs 76%; grade ≥3 TRAEs 74%; sintilimab added to CCRT improved EFS in locally advanced NPC PMID:24952746.
• Anti-CTLA-4 IBI-310 evaluated in combination with sintilimab in R/M NPC to address compensatory CTLA-4 checkpoint upregulation PMID:24952746.
• Anti-PD-1 agent whose efficacy in biliary tract cancer is reduced by Proteobacteria dominance in gut microbiota composition; microbiota-modulation strategies require careful design to avoid antibiotic-induced immunotherapy resistance PMID:25608663

Resistance mechanisms

Cancer types (linked)

• NPC

Sources

This page was processed by crosslinker on 2026-05-14. - PMID:25608663

This page was processed by crosslinker on 2026-05-14.